259 related articles for article (PubMed ID: 15163282)
1. Extended-release niacin for modifying the lipoprotein profile.
Guyton JR
Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
[TBL] [Abstract][Full Text] [Related]
2. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
3. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Moon YS; Kashyap ML
Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
[TBL] [Abstract][Full Text] [Related]
5. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Yim BT; Chong PH
Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
[TBL] [Abstract][Full Text] [Related]
6. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
Gupta EK; Ito MK
Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
[TBL] [Abstract][Full Text] [Related]
8. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Bays HE; McGovern ME
Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
Goldberg AC
Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
[TBL] [Abstract][Full Text] [Related]
13. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.
McCormack PL; Keating GM
Drugs; 2005; 65(18):2719-40. PubMed ID: 16392885
[TBL] [Abstract][Full Text] [Related]
14. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
15. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
17. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
18. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug.
Carlson LA
Int J Clin Pract; 2004 Jul; 58(7):706-13. PubMed ID: 15311728
[TBL] [Abstract][Full Text] [Related]
19. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
Crouse JR
Coron Artery Dis; 1996 Apr; 7(4):321-6. PubMed ID: 8853585
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
